Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 841 to 850 of 1090 total matches.
Extended-Release Hydrocodone (Hysingla ER) for Pain
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved a second extended-release (ER)
formulation of the oral opioid agonist hydrocodone
(Hysingla ER – Purdue) for management of pain severe
enough to require continuous long-term therapy and
for which alternative treatment options are inadequate.
Hysingla ER tablets have abuse-deterrent properties
to discourage their misuse.
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
treatment.10
DRUG INTERACTIONS — Artesunate is a substrate of
P-glycoprotein (P-gp) and breast cancer ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
or milk production. The drug is secreted into the
milk of lactating rats.
DRUG INTERACTIONS — Use ...
The FDA has approved solriamfetol (Sunosi – Jazz),
a dopamine and norepinephrine reuptake inhibitor
(DNRI), to improve wakefulness in adults with excessive
daytime sleepiness (EDS) associated with narcolepsy
or obstructive sleep apnea (OSA). Pitolisant (Wakix),
an H3-receptor antagonist/inverse agonist recently
approved by the FDA for treatment of excessive
daytime sleepiness in patients with narcolepsy, will be
reviewed in a future issue.
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
conduction
delays.
Ozanimod interacts with many other drugs, including MAO
inhibitors, serotonergic drugs ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • Sep 28, 2015 (Issue 1478)
because of an immature bloodbrain
barrier.
DRUG INTERACTIONS — Coadministration of
naloxegol ...
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Vytorin: A Combination of Ezetimibe and Simvastatin
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
with acute coronary syndromes. JAMA
2004; 292:1307.
7. Drug Interactions. Med Lett Drugs Ther 2003; 45:46 ...
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 03, 2014 (Issue 1437)
only through a restricted access program.
DRUG INTERACTIONS — Because of the risk of hypotension ...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016 (Issue 1488)
each.
DRUG INTERACTIONS — Selexipag and its active
metabolite are partially metabolized by CYP2C8 ...
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral prostacyclin analog,
was approved earlier for this indication.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
treatment is
$83,000.
204
DRUG INTERACTIONS — Ofatumumab may reduce
the efficacy of vaccines. Live ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
Cariprazine (Vraylar) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
mortality. Cariprazine is secreted into the milk of
lactating rats.
DRUG INTERACTIONS — Cariprazine ...
The FDA has approved the second-generation
antipsychotic drug cariprazine (Vraylar — Abbvie) for
adjunctive treatment of major depressive disorder
(MDD) in adults. Cariprazine was previously approved
for treatment of schizophrenia and bipolar depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6 doi:10.58347/tml.2023.1677c | Show Introduction Hide Introduction